Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease

Costache, Irina Iuliana; Garleanu, Irina; Aursulesei, Viviana; Namat, Razan Al; Ion, Adriana; Miftode, Radu Stefan; Tesloianu, Dan; Iliescu, Dan; Petris, Antoniu Octavian; Costache, Alexandru Dan; Popa, Delia Melania; Timpau, Amalia Stefana

Irina Iuliana Costache, Irina Garleanu, Viviana Aursulesei, Razan Al Namat, Adriana Ion, Radu Stefan Miftode, Dan Tesloianu, Dan Iliescu, Antoniu Octavian Petris, Alexandru Dan Costache, Delia Melania Popa, Amalia Stefana Timpau

Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease

Abstract:

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat accumulation after ruling out other causes of hepatic steatosis. The aim of the study is to identify the role of statin therapy in dyslipidemic patients with very high cardiovascular risk and NAFLD in achieving low density lipoprotein (LDL) cholesterol targets while also evaluating the changes in liver enzymes levels. This prospective study included 140 patients with NAFLD, hyperlipidemia and elevated cardiovascular risk. Serum lipids were assessed and liver function tests were performed at baseline and at 6 months follow up in 10 mg/ 20 mg daily atorvastatin treatment schedule. The results showed that total cholesterol, LDL cholesterol and triglycerides were significantly reduced at 6 months follow-up, while high density lipoprotein (HDL) cholesterol has not undergone important changes. Statin treatment significantly improved alanine aminotransferase serum levels, whereas aspartate aminotransferase levels were not significantly reduced between baseline and follow-up. Although statin therapy appears to be safe and effective for use in patients with NAFLD, an insufficient treatment is commonly observed in clinical practice, in order to avoid liver damage . NAFLD is not only a major cause of liver related morbidity and mortality, but also an independent cardiovascular risk factor, with cardiovascular mortality being the most important cause of death. Therefore, detecting and modifying risk factors without impairing liver function is desirable.

Keywords:
nonalcoholic fatty liver disease; cardiovascular risk; atorvastatin; dyslipidemia

Issue: 2019, Volume 70, Issue 6

Pages: 2159-2161

Publication date: 2019/7/15

https://doi.org/10.37358/RC.19.6.7296

Download Pdf Article

This article is published under the Creative Commons Attribution 4.0 International License

Citation Styles

Cite this article as:
COSTACHE, I.I., GARLEANU, I., AURSULESEI, V., NAMAT, R.A., ION, A., MIFTODE, R.S., TESLOIANU, D., ILIESCU, D., PETRIS, A.O., COSTACHE, A.D., POPA, D.M., TIMPAU, A.S., Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease, Rev. Chim., 70(6), 2019, 2159-2161.

Vancouver
Costache II, Garleanu I, Aursulesei V, Namat RA, Ion A, Miftode RS, Tesloianu D, Iliescu D, Petris AO, Costache AD, Popa DM, Timpau AS. Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease. Rev. Chim.[internet]. 2019 Jun;70(6):2159-2161. Available from: https://doi.org/10.37358/RC.19.6.7296

APA 6th edition
Costache, I.I., Garleanu, I., Aursulesei, V., Namat, R.A., Ion, A., Miftode, R.S.,... Timpau, A.S. (2019). Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease. Revista de Chimie, 70(6), 2159-2161. https://doi.org/10.37358/RC.19.6.7296

Harvard
Costache, I.I., Garleanu, I., Aursulesei, V., Namat, R.A., Ion, A., Miftode, R.S., Tesloianu, D., Iliescu, D., Petris, A.O., Costache, A.D., Popa, D.M., Timpau, A.S. (2019). 'Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease', Revista de Chimie, 70(6), pp. 2159-2161. https://doi.org/10.37358/RC.19.6.7296

IEEE
I.I. Costache, I. Garleanu, V. Aursulesei, R.A. Namat, A. Ion, R.S. Miftode, D. Tesloianu, D. Iliescu, A.O. Petris, A.D. Costache, D.M. Popa, A.S. Timpau, "Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease". Revista de Chimie, vol. 70, no. 6, pp. 2159-2161, 2019. [online]. https://doi.org/10.37358/RC.19.6.7296

Text
Irina Iuliana Costache, Irina Garleanu, Viviana Aursulesei, Razan Al Namat, Adriana Ion, Radu Stefan Miftode, Dan Tesloianu, Dan Iliescu, Antoniu Octavian Petris, Alexandru Dan Costache, Delia Melania Popa, Amalia Stefana Timpau,
Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease,
Revista de Chimie,
Volume 70, Issue 6,
2019,
Pages 2159-2161,
ISSN 2668-8212,
https://doi.org/10.37358/RC.19.6.7296.
(https://revistadechimie.ro/Articles.asp?ID=7296)
Keywords: nonalcoholic fatty liver disease; cardiovascular risk; atorvastatin; dyslipidemia

RIS
TY - JOUR
T1 - Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease
A1 - Costache, Irina Iuliana
A2 - Garleanu, Irina
A3 - Aursulesei, Viviana
A4 - Namat, Razan Al
A5 - Ion, Adriana
A6 - Miftode, Radu Stefan
A7 - Tesloianu, Dan
A8 - Iliescu, Dan
A9 - Petris, Antoniu Octavian
A10 - Costache, Alexandru Dan
A11 - Popa, Delia Melania
A12 - Timpau, Amalia Stefana
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2019
VL - 70
IS - 6
SP - 2159
EP - 2161
UR - https://doi.org/10.37358/RC.19.6.7296
KW - nonalcoholic fatty liver disease
KW - cardiovascular risk
KW - atorvastatin
KW - dyslipidemia
ER -

BibTex
@article{RevCh2019P2159,
author = {Costache Irina Iuliana and Garleanu Irina and Aursulesei Viviana and Namat Razan Al and Ion Adriana and Miftode Radu Stefan and Tesloianu Dan and Iliescu Dan and Petris Antoniu Octavian and Costache Alexandru Dan and Popa Delia Melania and Timpau Amalia Stefana},
title = {Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease},
journal = {Revista de Chimie},
volume = {70},
number = {6},
pages = {2159-2161},
year = {2019},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.19.6.7296},
url = {https://revistadechimie.ro/Articles.asp?ID=7296}
}

<<<< back

PUBLISHING SECTION

Author Guidelines

* Paper Drafting

* Paper Template

* Ethical Statement

* Paper Submission

Ghidul Autorului (ro)

Open Access & Archiving Policy

Search Authors

LATEST NEWS
	NUMAR OMAGIAL PETRU PONI.. detalii
	Revista de Chimie - 70 de ani de aparitie neintrerupta.. detalii
	English-Romanian Dictionary for Mechanical Engineering (download pdf)

News, Events

Gold Open Access | Source=http://www.plos.org/ | Author=art designer at PLoS

Conferences of Contemporary
Chemistry

Biblioteca Chimiei

Materiale Plastice

REVISTA DE CHIMIE

About

Board

Indexing